Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Gains from Investment Securities (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Gains from Investment Securities data on record, last reported at $1.4 million in Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 668.23% year-over-year to $1.4 million; the TTM value through Sep 2025 reached $1.4 million, up 727.99%, while the annual FY2024 figure was $385000.0, 39.22% down from the prior year.
  • Gains from Investment Securities reached $1.4 million in Q3 2025 per PLX's latest filing, up from $33000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.4 million in Q3 2025 and bottomed at -$526000.0 in Q3 2022.
  • Average Gains from Investment Securities over 5 years is $158943.9, with a median of $30500.0 recorded in 2022.
  • The widest YoY moves for Gains from Investment Securities: up 1233.33% in 2022, down 2048.15% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at -$30000.0 in 2021, then crashed by 453.33% to -$166000.0 in 2022, then soared by 203.61% to $172000.0 in 2023, then skyrocketed by 122.09% to $382000.0 in 2024, then surged by 279.32% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $1.4 million in Q3 2025, $33000.0 in Q1 2025, and $382000.0 in Q4 2024.